Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press14810.17650/1726-9776-2013-9-4-55-58PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫRADICAL PROSTATECTOMY IN PATIENTS OVER 70 YEARS OF AGE: SURVIVAL ANALYSISРАДИКАЛЬНАЯ ПРОСТАТЭКТОМИЯ У ПАЦИЕНТОВ СТАРШЕ 70 ЛЕТ: АНАЛИЗ ВЫЖИВАЕМОСТИVeliyevE. I.ВелиевЕ. И.
Russian Federation

Department of Urology and Surgical Andrology

кафедра урологии и хирургической андрологии

rmapo@yandex.ruSokolovE. A.СоколовЕ. А.
Russian Federation

Department of Urology and Surgical Andrology

кафедра урологии и хирургической андрологии

rmapo@yandex.ruPetrovS. B.ПетровС. Б.
Russian Federation
rmapo@yandex.ruLoranO. B.ЛоранО. Б.
Russian Federation

Department of Urology and Surgical Andrology

кафедра урологии и хирургической андрологии

rmapo@yandex.ruRussian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation, MoscowГБОУ ДПО РМАПО МЗ РФ, МоскваA. M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, Ministry of Emergency Situations of Russia, Saint PetersburgФГБУ «Всероссийский центр экстренной и радиационной медицины им. А. М. Никифорова» МЧС России, Санкт-Петербург301220139455582907201429072014https://oncourology.abvpress.ru/oncur/article/view/148

The possible benefits of radical surgical treatment for prostate cancer in elderly patients are controversial. The data of 1367 patients who had undergone radical prostatectomy (RPE) in the Clinics of Urology, S. P. Kirov Military Medical Academy, in 1997 to 2003 and in the Clinic of Urology, Russian Medical Academy of Postgraduate Education, in 2001 to 2010 were retrospectively analyzed. In the patient age group of ≥70 years, the five- and ten-year relapse-free survival rates were 76.4 and 70 %, respectively. In that of < 70 years, those were 79.1 and 75.4 % (p = 0.76). The five- and ten-year overall survival rates were 88.5 and 75.4 % in the patients aged ≥ 70 years and 95.2 and 87.7 % in those aged with < 70 years (p = 0.02). The ten-year cancer-specific survival rate was 99.1 and 95.6 % in the groups of ≥ 70 and < 70 years, respectively. The cause of death was cardiovascular diseases in more than half of the patients over 70 years of age (52.9 % of all deaths; 7.4 % of the entire cohort). In the patients aged above 70 years, indications for surgical treatment should be individually determined via aggregate assessment of cancer potential, surgical and anesthetic risks, and life expectancy.

prostate cancerradical prostatectomybiochemical recurrencesurvivalрак предстательной железырадикальная простатэктомиябиохимический рецидиввыживаемость1. Bosetti C., Bertuccio P., Chatenoud L. et al. Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 2011;60 (1):1–15.Bosetti C., Bertuccio P., Chatenoud L. et al. Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 2011;60 (1):1–15.2. Anandadas C. N., Clarke N. N., Davidson S. E. et al. Early prostate cancer – which treatment do men prefer and why? BJU Int 2011;107:1762–8.Anandadas C. N., Clarke N. N., Davidson S. E. et al. Early prostate cancer – which treatment do men prefer and why? BJU Int 2011;107:1762–8.3. Велиев Е. И., Петров С. Б., Лоран О. Б. и др. Радикальная позадилонная простатэктомия: первый российский опыт 15‑летнего наблюдения после операции. Онкоурология 2013;2:57–62.Велиев Е. И., Петров С. Б., Лоран О. Б. и др. Радикальная позадилонная простатэктомия: первый российский опыт 15‑летнего наблюдения после операции. Онкоурология 2013;2:57–62.4. Mullins J. K., Feng Z., Trock B. J. et al. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30‑year anniversary. J Urol 2012;188: 2219–24.Mullins J. K., Feng Z., Trock B. J. et al. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30‑year anniversary. J Urol 2012;188: 2219–24.5. Porter C. R., Kodama K., Gibbons R. P. et al. 25‑Year prostate cancer control and survival outcomes: a 40‑year radical prostatectomy single institution series. J Urol 2006;176:569–74.Porter C. R., Kodama K., Gibbons R. P. et al. 25‑Year prostate cancer control and survival outcomes: a 40‑year radical prostatectomy single institution series. J Urol 2006;176:569–74.6. Isbarn H., Wanner M., Salomon G. et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2009;106:37–43.Isbarn H., Wanner M., Salomon G. et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2009;106:37–43.7. Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Eng J Med 2011;364:1708–17.Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Eng J Med 2011;364:1708–17.8. Sanda M. G., Dunn R. L., Michalski J. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Eng J Med 2008;358:1250–61.Sanda M. G., Dunn R. L., Michalski J. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Eng J Med 2008;358:1250–61.9. Miller D. C., Gruber S. B., Hollenbeck B. K. et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134–41.Miller D. C., Gruber S. B., Hollenbeck B. K. et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134–41.10. Суринов А. Е., Збарская И. А., Антонова О. И. и др. Демографический ежегодник России 2010. М.: Росстат, 2010.Суринов А. Е., Збарская И. А., Антонова О. И. и др. Демографический ежегодник России 2010. М.: Росстат, 2010.11. Tewari A., Raman J. D., Chang P. et al. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 2006;1268–74.Tewari A., Raman J. D., Chang P. et al. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 2006;1268–74.12. Kane C. J., Im R., Amling C. L. et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from SEARCH database. Urology 2010;76:695–700.Kane C. J., Im R., Amling C. L. et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from SEARCH database. Urology 2010;76:695–700.13. D'Amico A. V., Whittington R., Malkowicz B. S. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.D'Amico A. V., Whittington R., Malkowicz B. S. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.14. Droz J. P., Balducci L., Bolla M. et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senor adults. Crit Rev OncolHematol 2010;73:68–91.Droz J. P., Balducci L., Bolla M. et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senor adults. Crit Rev OncolHematol 2010;73:68–91.15. Albertsen P. C., Moore D. F., Shih W. et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29:1335–41.Albertsen P. C., Moore D. F., Shih W. et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29:1335–41.16. Walz J., Gallina A., Saad F. et al. A nomogram predicting 10‑year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007;25:3576–81.Walz J., Gallina A., Saad F. et al. A nomogram predicting 10‑year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007;25:3576–81.17. Parsons K. J. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rev 2010;5:212–8.Parsons K. J. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rev 2010;5:212–8.18. Pierorazio P. M., Humphreys E., Walsh P. C. et al. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int 2009;106:791–5.Pierorazio P. M., Humphreys E., Walsh P. C. et al. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int 2009;106:791–5.19. Mullins J. K., Han M., Pierorazio P. M. et al. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 2012;187:1620–5.Mullins J. K., Han M., Pierorazio P. M. et al. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 2012;187:1620–5.